Form 4 Filing for Acrivon Therapeutics, Inc. - Officer Transaction

This filing details a transaction by Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. On May 18, 2026, Miller acquired 49,830 shares of Common Stock. The transaction code "A" and a price of "$0.00" indicate this was likely a grant of restricted stock units (RSUs). The shares acquired represent RSUs, with 16.67% vesting on November 18, 2026, and the remainder vesting quarterly thereafter, subject to continued service. Following this transaction, Miller holds 82,767 shares. This transaction is classified as direct ownership.